Brexit: UK Joining US-Led Project Orbis To Speed Cancer Drug Approvals
Executive Summary
Joining the international regulatory collaboration could become a key route for the UK to remain an early and priority market for global launches after the end of the Brexit transition period, says the industry group, BIA.
You may also be interested in...
Project Orbis: More Cancer Drugs Available In Scotland Than England
The UK joined Project Orbis in 2021 with the aim of speeding up the regulatory process for promising cancer drugs, but fewer than half of the drugs licensed under this pathway are available on the NHS in England.
‘Innovation Passport’ Necessary For UK Project Orbis Reviews
Promising cancer medicines will need to be included in the UK’s new licensing pathway for innovative drugs before the UK medicines regulator will agree to their review under the Project Orbis initiative.
Brexit: MHRA Joins Second International Work-Sharing Scheme To Speed Up Drug Approvals
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.